Tokio Marine Asset Management Co. Ltd. Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 18,140 shares of the medical research company’s stock after purchasing an additional 1,480 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $1,197,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in EW. Price T Rowe Associates Inc. MD raised its holdings in Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after purchasing an additional 2,390,137 shares during the period. Swedbank AB bought a new position in shares of Edwards Lifesciences in the first quarter worth approximately $124,511,000. Bank of New York Mellon Corp increased its stake in shares of Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after purchasing an additional 809,605 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Edwards Lifesciences by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after purchasing an additional 600,994 shares during the period. Finally, AustralianSuper Pty Ltd boosted its holdings in Edwards Lifesciences by 17.8% in the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock worth $216,013,000 after buying an additional 494,604 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on EW. Stifel Nicolaus cut their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Canaccord Genuity Group reduced their price target on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, October 25th. Robert W. Baird dropped their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $67.76 on Friday. The stock’s fifty day moving average price is $67.42 and its two-hundred day moving average price is $76.37. The firm has a market cap of $39.96 billion, a PE ratio of 9.78, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same period last year, the company earned $0.59 earnings per share. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,250 shares of company stock valued at $2,744,438 over the last ninety days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.